other material
confidence high
sentiment positive
materiality 0.75
Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK
Jade Biosciences, Inc.
- Mean IgA reduction ~70% from baseline, sustained at 12 weeks with single 700 mg dose; steady-state simulation supports Q12W dosing.
- JADE101 estimated 379-fold more potent than sibeprenlimab and 26-fold more potent than povetacicept in IgA-lowering.
- Favorable safety: no serious AEs, no discontinuations, no hypogammaglobulinemia; most common AEs were headache (25%), URTI (21.9%).
- Half-life at steady state ~8.7x longer than povetacicept and ~2.6x longer than sibeprenlimab, supporting convenient dosing (4 injections/year).
- Phase 2 JUNIPER trial ongoing; registrational Phase 3 planned for H1 2027.